27% had an aortic arch angulation of <= 110 degrees and 24% had descending thoracic aorta angulation of <= 90 degrees. Significant ostial stenosis was identified in 31% of celiac arteries, 7% superior A-1155463 inhibitor mesenteric arteries, 24% left renal artery and 19% right renal arteries. 11% of left common iliac and 7% right common iliac arteries had angulation of <= 70 degrees.
There were 26 cases with aortic dissection and 54% of these had a true lumen of <= 26 mm.
Conclusion: Successful fenestrated/branched stent graft repair of TAAAs requires adequate landing zones, cannulation of-visceral
arteries and suitable diameter access vessels. 60% of TAAAs studied were suitable for branched/fenestrated stent graft repair but 40% of TAAAs were unsuitable; aortic angulation, visceral vessel ostial stenosis and dissection true lumen diameter were the principle issues. Development in stent technology may address these anatomical challenges. (C) 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.”
“Poly-ADP-ribose polymerases (PARP) are involved in a number of processes that are vital for every
living cell. Once activated by the presence of DNA damage they trigger poly-ADP-ribosylation of various proteins which are crucial for DNA repair, preserving of genom integrity, regulation of transcription, Selleckchem Stem Cell Compound Library proliferation and apoptosis. PARP1,
which is the best known enzyme of PARP protein family, plays a role in single-strand HSP990 solubility dmso breaks (SSB) repair. Decrease of its activity results in accumulation of single strand DNA breaks (SSB) which leads as a consequence to double- strand breaks (DSBs). This disorder is particularly harmful to cells with deficiency of BRCA1/2 protein which is involved in repair of DNA double-strand breaks.
This phenomenon is an example of “”synthetic lethality”" concept and contributes to research on application of PARP inhibitors in treatment of cancers associated with BRCA1/2 protein defect (breast or ovarian cancer).
Noticed synergism between PARP inhibitors and genotoxic chemotherapy or radiotherapy determined another direction of research on application of these medicaments.
After promising results of phase I and II trials with most commonly investigated PARP inhibitors – iniparib and olaparib-which recruited patients with triple negative breast cancer and ovarian cancer, further studies started. This paper presents theoretical basis of PARP inhibitors action as well as critical review of most important clinical trials of these medicaments.”
“UV-Vis spectrometry has become a widespread analytical technique due to its inherent features (e.g., simplicity, ease of operation, convenience and economy).